Valuation: Seres Therapeutics, Inc.

Market Cap 20.99M 18.75M 17.32M 15.69M 29.36M 1.99B 29.85M 208M 82.51M 1.04B 78.79M 77.11M 3.29B P/E 2026 *
-0.59x
P/E 2027 * -0.42x
Enterprise Value 20.99M 18.75M 17.32M 15.69M 29.36M 1.99B 29.85M 208M 82.51M 1.04B 78.79M 77.11M 3.29B EV / Sales 2026 *
1.52x
EV / Sales 2027 * 76.8x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-1.88%
1 week-15.04%
Current month-37.61%
1 month-44.85%
3 months-60.04%
6 months-74.17%
Current year-85.95%
1 week 2
Extreme 2
2.58
1 month 2
Extreme 2
3.7
Current year 2
Extreme 2
16.42
1 year 2
Extreme 2
29.98
3 years 2
Extreme 2
41
5 years 2
Extreme 2
233.8
10 years 2
Extreme 2
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
Chief Executive Officer 58 01/08/2025
President 51 02/03/2026
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
17/8/26 Sell

General Counsel

-82 0.0008%
17/8/26 Sell

Director

-263 0.0027%
17/8/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-1.88%-15.04%-88.21%-93.17% 20.99M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.06%+0.67%+35.73%+132.48% 38.31B
Weighted average by Cap. +0.39%+2.73%+47.56%+158.56%

Financials

2026 *2027 *
Net sales 13.8M 12.32M 11.38M 10.31M 19.3M 1.31B 19.62M 137M 54.23M 686M 51.78M 50.68M 2.16B 274K 244K 226K 204K 383K 25.96M 389K 2.72M 1.07M 13.6M 1.03M 1M 42.89M
Net income -37.49M -33.48M -30.93M -28.03M -52.43M -3.56B -53.3M -372M -147M -1.86B -141M -138M -5.88B -78.95M -70.51M -65.13M -59.03M -110M -7.5B -112M -784M -310M -3.93B -296M -290M -12.38B
Net Debt - -
Projected Income Statement - Annual - Seres Therapeutics, Inc.
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
23/10/26 US$2.090 -1.88% 69,713
22/10/26 US$2.130 -7.39% 132,204
21/10/26 US$2.300 -0.43% 41,768
20/10/26 US$2.310 -4.55% 66,980
19/10/26 US$2.420 -1.63% 23,365
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Seres Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.090USD
Average target price
17.00USD
Spread / Average Target
+713.40%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Seres Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. MCRB Stock